You're contacting media contact of this press release

Title: Andarix Pharmaceuticals CEO to Participate in Panel on AI in Clinical Trials at 26th BioPharma Clinical Trials Nexus

Boston, MA, United States, 7th May 2026 - Andarix Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation targeted radiopharmaceuticals for oncology, today announced that Chief Executive Officer Christopher P. Adams will serve as a panelist at the 26th BioPharma Clinical Trials Nexus conference. Mr. Adams will participate in the panel discussion titled “AI in Clinical Trials: Innovation, Challenges, and Execution in Modern Trial Development,” scheduled for Day 1 of the conference from 11:55 AM to 12:50 PM. The panel will bring together senior leaders from across the biopharmaceutical industry to examine the growing role of artificial intelligence in clinical trial design, data management, and operational execution. Topics are expected to include practical applications of AI in trial development, the regulatory and ethical considerations surrounding its adoption, and strategies for integrating AI-driven tools into existing clinical infrastructure. Mr. Adams will join fellow panelists from AstraZeneca, Ultragenyx Pharmaceutical, Bristol Myers Squibb, and Inferential Data LLC, moderated by Dr. Divesh Kumar, Global Head of Biowelness Lifescience Pvt. Ltd. “AI is fundamentally reshaping how clinical trials are designed and executed, and I look forward to sharing Andarix’s perspective on how emerging technologies can accelerate development timelines while maintaining rigorous scientific standards,” said Christopher P. Adams, CEO of Andarix Pharmaceuticals. “For a clinical-stage company like Andarix, the ability to leverage data-driven tools to optimize patient selection and trial efficiency is directly relevant to advancing our pipeline toward meaningful patient outcomes.” The 26th BioPharma Clinical Trials Nexus is a premier...

This press release is issued by King Newswire